FibroGen Inc (FGEN) Shares Sold by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. lowered its position in FibroGen Inc (NASDAQ:FGEN) by 34.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 163,500 shares of the biopharmaceutical company’s stock after selling 85,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.20% of FibroGen worth $7,750,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Bank of Montreal Can increased its position in shares of FibroGen by 2,097.2% in the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. increased its position in shares of FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 1,700 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of FibroGen by 41.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 1,147 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its position in shares of FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,336 shares in the last quarter. Institutional investors and hedge funds own 56.78% of the company’s stock.

Shares of FibroGen Inc (NASDAQ:FGEN) opened at $56.40 on Thursday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen Inc has a 52 week low of $22.75 and a 52 week high of $63.00.

In related news, insider K Peony Yu sold 7,500 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $53.97, for a total transaction of $404,775.00. Following the sale, the insider now owns 144,986 shares of the company’s stock, valued at $7,824,894.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.66, for a total value of $1,725,483.76. Following the completion of the sale, the chief executive officer now directly owns 3,022,934 shares in the company, valued at $135,004,232.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 299,517 shares of company stock worth $14,852,726. Corporate insiders own 13.60% of the company’s stock.

A number of brokerages have recently weighed in on FGEN. ValuEngine upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research report on Thursday, November 9th. Four analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. FibroGen has an average rating of “Buy” and a consensus target price of $65.67.

COPYRIGHT VIOLATION WARNING: “FibroGen Inc (FGEN) Shares Sold by Candriam Luxembourg S.C.A.” was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2018/02/15/fibrogen-inc-fgen-shares-sold-by-candriam-luxembourg-s-c-a.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply